Compare DFI Retail Nusantara Tbk. (HERO) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DFI Retail Nusantara Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? DFI Retail Nusantara Tbk. trades at Rp334 (market cap 1.41T, 46.7K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: DFI Retail Nusantara Tbk. is far larger — about 13.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| HERO | SCPI | |
|---|---|---|
Market Cap | 1.41T | 104.4B |
Volume | 46.7K | — |
Lot | 467 | — |
Turnover | 15.36M | — |
Average Price | 328.81 | — |
Value | 15.36M | — |
Indicative Equilibrium Price | 340 | — |
Indicative Equilibrium Volume | 7 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DFI Retail Nusantara Tbk.
The company began its commercial operations in August 1972. Hero is Indonesia’s largest supermarket chain with a network of 66 supermarkets, consisting of 44 stores in Greater Jakarta and 22 stores in major regional cities. Supermarket operations account for about 90% of sales complemented by an array of retail formats including convenience stores, mini markets, and pharmacies. The company’s mission is to be the leading modern food retailer in Indonesia in terms of sales and profits, targeting the middle to upper income consumer segments where buying power is greatest. As the economy begins to gather strength, HERO has relatively aggressive expansion plans drawing upon its established brand, a reputation for fresh quality foods, friendly experienced staff, best service, a leading position in category and space management and efficient centralized distribution infrastructure. In 1998 the acquisition of a 32% effective interest in Hero by Dairy Farm International contributed significant international experience and expertise to the local knowledge and insight of Hero’s management as well as recognition of the potential of Indonesia as one of the most attractive growth markets in South East Asia over the medium long term.
Read more on HERO →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
